Bioadaptives Financials
Bioadaptives (BDPT) reported $18K in revenue for fiscal year 2025, up 44.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The dominant mechanic is financing-led operation: gross-margin recovery is being overwhelmed by overhead, cash losses, and a liability-heavy balance sheet.
Between FY2024 and FY2025, gross margin expanded from31.8% to68.4% . Yet operating margin worsened to-57.0% while SG&A reached$821K , showing that better direct economics did not translate into operating control.
Revenue recovered to
FY2025 operating cash flow of
Financial Health Signals
Bioadaptives does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Bioadaptives scores -92.97, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($17K) relative to total liabilities ($2.4M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Bioadaptives passes 2 of 5 computable financial strength tests (4 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Bioadaptives reported an operating loss of $1.0M against $71K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Bioadaptives generated $18K in revenue in fiscal year 2025. This represents an increase of 44.3% from the prior year.
Bioadaptives's EBITDA was -$1.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 73.0% from the prior year.
Bioadaptives earned -$0.15 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 36.4% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Bioadaptives recorded an outflow of $534K in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 114.0% from the prior year.
Bioadaptives held $215K in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Bioadaptives's gross margin was 68.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 36.6 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Bioadaptives invested $18K in capex in fiscal year 2025, funding long-term assets and infrastructure.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
BDPT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5K-9.5% | $6K | N/A | $5K+43.9% | $3K | $0 | N/A | $0 |
| Cost of Revenue | $748-46.6% | $1K | N/A | $781-63.8% | $2K | $0 | N/A | $0 |
| Gross Profit | $4K+3.1% | $4K | N/A | $4K+262.3% | $1K | $0 | N/A | $0 |
| SG&A Expenses | $178K-1.8% | $181K | N/A | $251K+26.8% | $198K+38.0% | $143K | N/A | $40K |
| Operating Income | -$197K+0.5% | -$198K | N/A | -$266K+4.8% | -$279K-12.1% | -$249K | N/A | -$122K |
| Interest Expense | $115K+31.1% | $88K | N/A | $14K+46.7% | $10K0.0% | $10K | N/A | $10K |
| Net Income | $150K+235.1% | -$111K | N/A | -$380K-140.3% | -$158K+19.9% | -$197K | N/A | -$38K |
| EPS (Diluted) | $0.00 | -$0.01+85.7% | -$0.07-75.0% | -$0.04-100.0% | -$0.020.0% | -$0.02+50.0% | -$0.04 | $0.00 |
Not reported in any period shown, so not listed: R&D Expenses, Income Tax.
BDPT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $79K-42.1% | $136K-39.8% | $226K+81.7% | $124K-54.4% | $273K+146.7% | $110K-57.8% | $262K+464.5% | $46K |
| Current Assets | $68K-45.1% | $123K-41.7% | $212K+94.7% | $109K-57.4% | $256K+131.3% | $110K-57.8% | $262K+464.5% | $46K |
| Cash & Equivalents | $29K-60.3% | $74K-65.8% | $215K+263.1% | $59K-71.9% | $211K+432.3% | $40K-84.9% | $262K+496.6% | $44K |
| Inventory | $36K-16.1% | $43K-3.9% | $45K+1.1% | $44K+11.8% | $40K-2.5% | $41K+112.3% | $19K | $0 |
| Accounts Receivable | N/A | N/A | N/A | $590.0% | $59 | N/A | $0 | N/A |
| Total Liabilities | $1.8M-18.8% | $2.3M-3.6% | $2.4M+48.2% | $1.6M+12.9% | $1.4M-16.3% | $1.7M-2.6% | $1.7M-6.8% | $1.9M |
| Current Liabilities | $1.8M-18.8% | $2.3M-3.6% | $2.4M+48.2% | $1.6M+12.9% | $1.4M-16.3% | $1.7M-2.6% | $1.7M-6.8% | $1.9M |
| Total Equity | -$1.8M+17.3% | -$2.1M-0.3% | -$2.1M-45.4% | -$1.5M-29.1% | -$1.1M+27.7% | -$1.6M-7.3% | -$1.5M+18.9% | -$1.8M |
| Retained Earnings | -$10.7M+1.4% | -$10.8M-1.0% | -$10.7M-8.3% | -$9.9M-4.0% | -$9.5M-1.7% | -$9.4M-2.2% | -$9.2M-4.2% | -$8.8M |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
BDPT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$44K+47.7% | -$85K+45.6% | -$156K-3.0% | -$151K-36.3% | -$111K-13.4% | -$98K+2.6% | -$101K-78.4% | -$56K |
| Capital Expenditures | N/A | N/A | $0 | $0 | N/A | N/A | $0 | $0 |
| Free Cash Flow | N/A | N/A | -$156K-3.0% | -$151K | N/A | N/A | -$101K-78.4% | -$56K |
| Investing Cash Flow | N/A | N/A | $0 | $0 | N/A | N/A | $0 | $0 |
| Financing Cash Flow | N/A | N/A | $255K | $0 | N/A | N/A | $194K+94.1% | $100K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BDPT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 85.0%+10.4pp | 74.6% | N/A | 83.1%+50.1pp | 33.0% | N/A | N/A | N/A |
| Operating Margin | -3953.0% | -3594.8% | N/A | -5735.9% | -8674.1% | N/A | N/A | N/A |
| Net Margin | 3009.0% | -2014.6% | N/A | -8193.0% | -4905.7% | N/A | N/A | N/A |
| Return on Assets | 190.6%+272.3pp | -81.7% | N/A | -305.2%-247.2pp | -58.0%+120.5pp | -178.5% | N/A | -81.2% |
| Current Ratio | 0.040.0x | 0.050.0x | 0.090.0x | 0.07-0.1x | 0.18+0.1x | 0.07-0.1x | 0.15+0.1x | 0.03 |
| FCF Margin | N/A | N/A | N/A | -3266.6% | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$2.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.09), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Bioadaptives Ranks
Frequently Asked Questions
What is Bioadaptives's annual revenue?
Bioadaptives (BDPT) reported $18K in total revenue for fiscal year 2025. This represents a 44.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Bioadaptives's revenue growing?
Bioadaptives (BDPT) revenue grew by 44.3% year-over-year, from $13K to $18K in fiscal year 2025.
What is Bioadaptives's EBITDA?
Bioadaptives (BDPT) had EBITDA of -$1.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Bioadaptives's gross margin?
Bioadaptives (BDPT) had a gross margin of 68.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Bioadaptives's free cash flow?
Bioadaptives (BDPT) recorded an outflow of $534K in free cash flow during fiscal year 2025. This represents a -114.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Bioadaptives's operating cash flow?
Bioadaptives (BDPT) recorded an outflow of $516K in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Bioadaptives's total assets?
Bioadaptives (BDPT) had $226K in total assets as of fiscal year 2025, including both current and long-term assets.
What are Bioadaptives's capital expenditures?
Bioadaptives (BDPT) invested $18K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Bioadaptives's current ratio?
Bioadaptives (BDPT) had a current ratio of 0.09 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
How does Bioadaptives's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Bioadaptives (BDPT) held $215K in cash, cash equivalents and investments, and reported an operating cash outflow of $516K over that year. Dividing the one by the other, the reported balance equals about 5 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Bioadaptives's debt-to-equity ratio negative or not reported?
Bioadaptives (BDPT) has negative shareholder equity of -$2.1M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Bioadaptives's Altman Z-Score?
Bioadaptives (BDPT) has an Altman Z-Score of -92.97, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Bioadaptives's Piotroski F-Score?
Bioadaptives (BDPT) has a Piotroski F-Score of 2 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Can Bioadaptives cover its interest payments?
Bioadaptives (BDPT) reported an operating loss of $1.0M against $71K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.